Profile data is unavailable for this security.
About the company
Lyra Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The Company has two investigational product candidates, LYR-210 and LYR-220, in late-stage development for CRS, a prevalent inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. LYR-210 and LYR-220 are bioresorbable nasal implants designed to be administered in a brief, in-office procedure and are intended to deliver six months of continuous mometasone furoate drug therapy to the sinonasal passages. LYR-210 is designed for surgically naive patients and is being evaluated in the ENLIGHTEN Phase III clinical program, while LYR-220, is being evaluated in the BEACON Phase II clinical trial in patients who have recurrent symptoms despite having had prior ethmoid sinus surgery.
- Revenue in USD (TTM)1.47m
- Net income in USD-97.61m
- Incorporated2005
- Employees87.00
- LocationLyra Therapeutics Inc480 Arsenal WayWATERTOWN 02472United StatesUSA
- Phone+1 (617) 373-4600
- Fax+1 (302) 655-5049
- Websitehttps://lyratherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnstone Biologics Corp | 0.00 | -74.42m | 10.64m | 81.00 | -- | 0.2437 | -- | -- | -3.23 | -3.23 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -78.42 | -- | -91.27 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -73.66 | -- | -78.05 | -- | -- | -- |
| Indaptus Therapeutics Inc | 0.00 | -14.89m | 10.81m | 7.00 | -- | 1.80 | -- | -- | -1.72 | -1.72 | 0.00 | 0.5887 | 0.00 | -- | -- | 0.00 | -114.42 | -66.55 | -138.96 | -81.23 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.68 | -- | -- | -- |
| Nascent Biotech Inc | 0.00 | -1.92m | 10.93m | -- | -- | -- | -- | -- | -0.012 | -0.012 | 0.00 | -0.003 | 0.00 | -- | -- | -- | -1,256.81 | -708.50 | -- | -- | -- | -- | -- | -589.83 | -- | -- | -- | -- | -- | -- | 25.47 | -- | -- | -- |
| ELEVAI Labs Inc | 2.45m | -5.47m | 11.08m | 18.00 | -- | 0.1235 | -- | 4.53 | -0.2924 | -0.2924 | 0.1303 | 0.1733 | 0.3826 | 0.9499 | 216.67 | 135,897.80 | -85.53 | -- | -121.34 | -- | 71.15 | -- | -223.57 | -- | 3.40 | -- | 0.00 | -- | 123.50 | -- | -138.94 | -- | -- | -- |
| NKGen Biotech Inc | 0.00 | -88.25m | 11.27m | 63.00 | -- | -- | -- | -- | -3.74 | -3.74 | 0.00 | -2.71 | 0.00 | -- | -- | 0.00 | -480.25 | -- | -- | -- | -- | -- | -- | -- | -- | -0.4822 | -- | -- | -100.00 | -- | -210.06 | -- | -- | -- |
| Lyra Therapeutics Inc | 1.47m | -97.61m | 11.65m | 87.00 | -- | 0.5651 | -- | 7.92 | -1.51 | -1.51 | 0.0229 | 0.315 | 0.0148 | -- | -- | 16,715.91 | -97.94 | -58.01 | -118.22 | -68.69 | -- | -- | -6,635.76 | -6,235.31 | -- | -- | 0.00 | -- | 14.31 | 4.60 | -13.39 | -- | 95.14 | -- |
| Viaderma Inc | 17.80m | 2.31m | 11.72m | 75.00 | 0.0006 | 0.00004 | 2.17 | 0.6585 | 16.84 | 16.84 | 129.62 | 255.59 | 0.4126 | 24.69 | 1.21 | 237,331.30 | 5.36 | -- | 6.53 | -- | 28.90 | -- | 12.99 | -- | 2.07 | 5.66 | 0.1718 | -- | -29.15 | -- | -40.70 | -- | -- | -- |
| Aspira Women's Health Inc | 8.92m | -15.95m | 11.73m | 64.00 | -- | -- | -- | 1.31 | -1.45 | -1.45 | 0.801 | -0.2892 | 1.53 | 15.11 | 5.79 | 139,421.90 | -273.16 | -110.58 | -3,758.30 | -151.88 | 57.84 | 45.23 | -178.80 | -334.08 | 0.5542 | -17,354.00 | -- | -- | 11.85 | 24.56 | 44.15 | -- | -26.65 | -- |
| Protext Mobility Inc | 750.00 | -2.21m | 11.87m | 4.00 | -- | -- | -- | 15,824.20 | -0.4692 | -0.4692 | 0.00001 | -0.0102 | 0.0405 | -- | -- | -- | -9,400.97 | -1,587.94 | -- | -- | 86.67 | -530.19 | -232,392.00 | -17,498.83 | 0.0002 | -1.36 | -- | -- | -93.98 | -63.09 | 27.35 | -- | -- | -- |
| Sol Gel Technologies Ltd | 11.71m | -9.57m | 12.29m | 36.00 | -- | 0.354 | -- | 1.05 | -0.3435 | -0.3435 | 0.4202 | 1.25 | 0.2522 | -- | 3.34 | 325,194.40 | -20.62 | -31.60 | -23.40 | -35.49 | -- | -- | -81.75 | -135.76 | -- | -- | 0.00 | -- | -59.98 | 64.50 | -82.52 | -- | -33.78 | -- |
| Sensei Biotherapeutics Inc | 0.00 | -29.80m | 12.53m | 28.00 | -- | 0.2736 | -- | -- | -1.19 | -1.19 | 0.00 | 1.82 | 0.00 | -- | -- | 0.00 | -44.18 | -47.03 | -48.36 | -54.33 | -- | -- | -- | -- | -- | -- | 0.0222 | -- | -- | -- | 29.82 | -- | 42.16 | -- |
| AIM ImmunoTech Inc | 201.00k | -28.05m | 12.74m | 26.00 | -- | 1.87 | -- | 63.39 | -0.5703 | -0.5703 | 0.004 | 0.1068 | 0.0082 | -- | 12.18 | 7,730.77 | -113.70 | -45.64 | -149.16 | -48.35 | 71.14 | -231.75 | -13,952.74 | -11,695.01 | -- | -- | 0.3018 | -- | 43.26 | -11.26 | -48.94 | -- | 35.73 | -- |
| HST Global Inc | 0.00 | -123.45k | 12.80m | 1.00 | -- | -- | -- | -- | -0.0209 | -0.0209 | 0.00 | -0.0004 | 0.00 | -- | -- | -- | -3,300.80 | -5,836.01 | -- | -- | -- | -- | -- | -- | -- | -27.31 | 5.81 | -- | -- | -- | -0.7858 | -- | -- | -- |
Data as of Nov 21 2024. Currency figures normalised to Lyra Therapeutics Inc's reporting currency: US Dollar USD
40.50%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Perceptive Advisors LLCas of 30 Sep 2024 | 12.76m | 19.49% |
| Citadel Advisors LLCas of 30 Sep 2024 | 4.77m | 7.29% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 2.98m | 4.56% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 1.71m | 2.61% |
| Ikarian Capital LLCas of 30 Sep 2024 | 1.06m | 1.62% |
| SEI Investments Management Corp.as of 30 Sep 2024 | 997.78k | 1.52% |
| Geode Capital Management LLCas of 30 Sep 2024 | 768.39k | 1.17% |
| Parametric Portfolio Associates LLCas of 30 Sep 2024 | 512.48k | 0.78% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 488.72k | 0.75% |
| Two Sigma Advisers LPas of 30 Sep 2024 | 460.30k | 0.70% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
